12.17.14
Eli Lilly and Co. has exercised its option to an exclusive worldwide license to develop and commercialize an XTEN product under a research collaboration with Amunix to develop new therapeutics targeting diabetes. Amunix will receive an option fee and is eligible to receive additional regulatory milestones, plus royalties on worldwide sales of the Lilly XTEN product in development. Further financial terms were not disclosed.
XTEN is a recombinant polypeptide that extends the in vivo half-life of therapeutics payloads. Pharmaceuticals such as proteins, peptides and synthetic compounds can be XTENylated via chemical conjugation or genetic fusion.
"This is an important milestone for the very productive collaboration that combined Lilly's deep expertise in the diabetes field with Amunix's capabilities of engineering long-acting pharmaceuticals," said Volker Schellenberger, PhD, Amunix president and chief executive officer. "Over the last year, we entered into a significant number of new partnerships and this latest milestone in our relationship with Lilly reinforces Amunix's leadership position in the field of half-life extension."
XTEN is a recombinant polypeptide that extends the in vivo half-life of therapeutics payloads. Pharmaceuticals such as proteins, peptides and synthetic compounds can be XTENylated via chemical conjugation or genetic fusion.
"This is an important milestone for the very productive collaboration that combined Lilly's deep expertise in the diabetes field with Amunix's capabilities of engineering long-acting pharmaceuticals," said Volker Schellenberger, PhD, Amunix president and chief executive officer. "Over the last year, we entered into a significant number of new partnerships and this latest milestone in our relationship with Lilly reinforces Amunix's leadership position in the field of half-life extension."